Kim Hong-Ju, Kim Daehoon, Kim Kipoong, Choi Sung Hwa, Kim Moon-Hyun, Park Je-Wook, Yu Hee Tae, Kim Tae-Hoon, Uhm Jae-Sun, Joung Boyoung, Lee Moon-Hyoung, Pak Hui-Nam
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital Yonsei University College of Medicine Seoul Republic of Korea.
Division of Cardiology, Department of Internal Medicine Yeungnam University College of Medicine Daegu Republic of Korea.
J Arrhythm. 2024 Jul 2;40(4):867-878. doi: 10.1002/joa3.13104. eCollection 2024 Aug.
The impact of delaying atrial fibrillation catheter ablation (AFCA) for antiarrhythmic drug (AAD) management on the disease course remains unclear. This study investigated AFCA rhythm outcomes based on the diagnosis-to-ablation time (DAT) and AAD responsiveness in participants with persistent AF (PeAF).
We included data from 1038 AAD-resistant PeAF participants, all of whom had a clear time point for AF diagnosis, especially PeAF at diagnosis time, and had undergone an AFCA for the first time. Participants who experienced recurrences of paroxysmal type on AAD therapy were analyzed as a cohort of AAD-partial responders; those maintaining PeAF on AAD were AAD-non-responders. We determined the DAT cutoff for best discriminating long-term rhythm outcomes using a maximum log-likelihood estimation method based on the Cox proportional hazard regression model.
Of the participants (79.8% male; median age 61), 806 (77.6%) were AAD-non-responders. AAD-non-responders had a higher body mass index and a larger left atrial diameter than AAD-partial-responders. They also had a higher incidence of AF recurrence after AFCA (adjusted hazard ratio 1.75, 95% confidence interval 1.33-2.30; log-rank < .001) compared to AAD-partial-responders. The maximum log-likelihood estimation showed bimodal cutoffs at 22 and 40 months. The optimal DAT cutoff rhythm outcome was 22 months, which discriminated better in the AAD-partial-responders than in the AAD-non-responders.
Both DAT and AAD responsiveness influenced AFCA rhythm outcomes. Delaying AFCA to a DAT of longer than 22 months was inadvisable, particularly in the participants in whom PeAF was changed to paroxysmal AF during AAD therapy.
抗心律失常药物(AAD)治疗时延迟心房颤动导管消融(AFCA)对疾病进程的影响尚不清楚。本研究在持续性房颤(PeAF)患者中,基于诊断至消融时间(DAT)和AAD反应性,调查了AFCA的节律结果。
我们纳入了1038例对AAD耐药的PeAF患者的数据,所有患者均有明确的房颤诊断时间点,尤其是诊断时为PeAF,且首次接受AFCA。在AAD治疗期间经历阵发性房颤复发的患者作为AAD部分反应者队列进行分析;在AAD治疗期间维持PeAF的患者为AAD无反应者。我们基于Cox比例风险回归模型,使用最大对数似然估计方法确定了最佳区分长期节律结果的DAT临界值。
在这些患者中(79.8%为男性;中位年龄61岁),806例(77.6%)为AAD无反应者。AAD无反应者的体重指数和左心房直径高于AAD部分反应者。与AAD部分反应者相比,他们在AFCA后房颤复发的发生率也更高(调整后风险比1.75,95%置信区间1.33 - 2.30;对数秩检验P <.001)。最大对数似然估计显示在22个月和40个月时有双峰临界值。最佳的DAT临界值节律结果为22个月,在AAD部分反应者中比在AAD无反应者中区分效果更好。
DAT和AAD反应性均影响AFCA的节律结果。将AFCA推迟至DAT超过22个月是不可取的,尤其是在AAD治疗期间PeAF转变为阵发性房颤的患者中。